Compile Data Set for Download or QSAR
Report error Found 93 Enz. Inhib. hit(s) with all data for entry = 11233
TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM50201027(CHEMBL3945735 | US10155727, Example 30 | USRE49517...)
Affinity DataIC50: 3.47E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311036(US10155727, Example 98 | USRE49517, Example 98)
Affinity DataIC50: 3.55E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM50201025(CHEMBL3975087 | US10155727, Example 26 | USRE49517...)
Affinity DataIC50: 4.75E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310970(US10155727, Example 24 | USRE49517, Example 24)
Affinity DataIC50: 4.89E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311034(US10155727, Example 95 | USRE49517, Example 95)
Affinity DataIC50: 6.36E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311004(US10155727, Example 59 | USRE49517, Example 59)
Affinity DataIC50: 7.28E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310961(US10155727, Example 15 | USRE49517, Example 15)
Affinity DataIC50: 7.93E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311035(US10155727, Example 96 | USRE49517, Example 96)
Affinity DataIC50: 7.96E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310958(US10155727, Example 12 | USRE49517, Example 12)
Affinity DataIC50: 8.06E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM50201021(CHEMBL3966599 | US10155727, Example 2 | USRE49517,...)
Affinity DataIC50: 8.08E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311011(US10155727, Example 66 | USRE49517, Example 66)
Affinity DataIC50: 8.86E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310969(US10155727, Example 23 | USRE49517, Example 23)
Affinity DataIC50: 9.24E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM50201022(CHEMBL3897632 | US10155727, Example 6 | USRE49517,...)
Affinity DataIC50: 9.56E+3nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311048(US10155727, Example 103 | USRE49517, Example 103)
Affinity DataIC50: 1.00E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311047(US10155727, Example 102 | USRE49517, Example 102)
Affinity DataIC50: 1.02E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311008(US10155727, Example 63 | USRE49517, Example 63)
Affinity DataIC50: 1.08E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311003(US10155727, Example 58 | USRE49517, Example 58)
Affinity DataIC50: 1.26E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311039(US10155727, Example 11 | USRE49517, Example 11)
Affinity DataIC50: 1.27E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310948(US10155727, Example 1 | USRE49517, Example 1)
Affinity DataIC50: 1.28E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311009(US10155727, Example 64 | USRE49517, Example 64)
Affinity DataIC50: 1.44E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310987(US10155727, Example 41 | USRE49517, Example 41)
Affinity DataIC50: 1.60E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310960(US10155727, Example 14 | USRE49517, Example 14)
Affinity DataIC50: 1.61E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311020(US10155727, Example 77 | USRE49517, Example 77)
Affinity DataIC50: 1.69E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310996(US10155727, Example 50 | USRE49517, Example 50)
Affinity DataIC50: 1.70E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310975(US10155727, Example 29 | USRE49517, Example 29)
Affinity DataIC50: 1.79E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310957(US10155727, Example 10 | USRE49517, Example 10)
Affinity DataIC50: 1.84E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310995(US10155727, Example 49 | USRE49517, Example 49)
Affinity DataIC50: 1.90E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310977(US10155727, Example 31 | USRE49517, Example 31)
Affinity DataIC50: 1.97E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311000(US10155727, Example 55 | USRE49517, Example 55)
Affinity DataIC50: 2.11E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310956(US10155727, Example 9 | USRE49517, Example 9)
Affinity DataIC50: 2.15E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310968(US10155727, Example 22 | USRE49517, Example 22)
Affinity DataIC50: 2.26E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310981(US10155727, Example 35 | USRE49517, Example 35)
Affinity DataIC50: 2.26E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310966(US10155727, Example 20 | USRE49517, Example 20)
Affinity DataIC50: 2.26E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310950(US10155727, Example 3 | USRE49517, Example 3)
Affinity DataIC50: 2.33E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310986(US10155727, Example 40 | USRE49517, Example 40)
Affinity DataIC50: 2.33E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311006(US10155727, Example 61 | USRE49517, Example 61)
Affinity DataIC50: 2.47E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311031(US10155727, Example 92 | USRE49517, Example 92)
Affinity DataIC50: 2.74E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310982(US10155727, Example 36 | USRE49517, Example 36)
Affinity DataIC50: 2.96E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311005(US10155727, Example 60 | USRE49517, Example 60)
Affinity DataIC50: 3.16E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310967(US10155727, Example 21 | USRE49517, Example 21)
Affinity DataIC50: 3.35E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM50201026(CHEMBL3983077 | US10155727, Example 17 | USRE49517...)
Affinity DataIC50: 3.50E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310973(US10155727, Example 27 | USRE49517, Example 27)
Affinity DataIC50: 3.51E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310959(US10155727, Example 13 | USRE49517, Example 13)
Affinity DataIC50: 3.70E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310994(US10155727, Example 48 | USRE49517, Example 48)
Affinity DataIC50: 3.74E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310983(US10155727, Example 37 | USRE49517, Example 37)
Affinity DataIC50: 3.81E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310978(US10155727, Example 32 | USRE49517, Example 32)
Affinity DataIC50: 3.86E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311010(US10155727, Example 65 | USRE49517, Example 65)
Affinity DataIC50: 4.04E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM310955(US10155727, Example 8 | USRE49517, Example 8)
Affinity DataIC50: 4.10E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311007(US10155727, Example 62 | USRE49517, Example 62)
Affinity DataIC50: 4.19E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

TargetPotassium voltage-gated channel subfamily H member 2(Human)
Janssen Pharmaceuticals

US Patent
LigandPNGBDBM311027(US10155727, Example 88 | USRE49517, Example 88)
Affinity DataIC50: 4.32E+4nMAssay Description:Binding was terminated by filtration of the incubated membrane preparations using Filtermat B (Pharmacia, Uppsala Sweden) and a Micro Cell Harvester ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/2/2023
Entry Details
US Patent

Displayed 1 to 50 (of 93 total ) | Next | Last >>
Jump to: